References
- Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-42
- WHO. Hepatitis C Factsheet April 2017
- Public Health England. Hepatitis C in the UK. July 2015. PHE publications gateway number: 2015208. 2015
- Economist Intelligence Unit. The silent pandemic: tackling hepatitis C with policy innovation. January 2013. 2013. https://www.eiuperspectives.economist.com/healthcare/tackling-hepatitis-c/article/silent-pandemic
- Scalone L, Fagiuoli S, Ciampichini R, et al. The societal burden of chronic liver diseases: results from the COME study. BMJ open Gastroenterol 2015;2:e000025
- Aggarwal J, Vera-Llonch M, Donepudi M, et al. Work productivity among treatment-naive patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. J Viral Hepat 2015;22:8-17
- Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterol Hepatol (NY) 2011;7:661-71
- Patruni B, Nolte E. Hepatitis C: A projection of the healthcare and economic burden in the UK. Santa Monica (CA): RAND Corporation; 2013
- Younossi Z, Brown A, Buti M, et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat. 2016;23:217-26. http://doi.wiley.com/10.1111/jvh.12483
- Auerbach AJ, Gokhale J, Kotlikoff LJ. Generational accounting: a meaningful way to evaluate fiscal policy. J Econ Perspect. 1994;8:73-94
- Connolly MP, Kotsopoulos N, Postma MJ, et al. The fiscal consequences attributed to changes in morbidity and mortality linked to investments in health care: a government perspective analytic framework. Value Heal J Int Soc Pharmacoeconomics Outcomes Res 2017;20:273-7
- Thokala P, Simpson EL, Tappenden P, et al. Ledipasvir-sofosbuvir for treating chronic hepatitis C: a NICE single technology appraisal – an evidence review group perspective. Pharmacoeconomics 2016;34:741-50
- Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-98.
- Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-93
- Connolly MP, Tashjian C, Kotsopoulos N, et al. A comparison of average wages with age-specific wages for assessing indirect productivity losses: analytic simplicity versus analytic precision. Eur J Heal Econ. 2017;18:697-701. Available at: https://doi.org/10.1007/s10198-016-0819-9
- Office National Statistics. Statistical bulletin: annual survey of hours and earnings, 2014 provisional results. Wiley Publishing. Office National Statistics; 2014
- Su J, Brook RA, Kleinman NL, et al. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 2010;52:436-42
- El Khoury AC, Vietri J, Prajapati G. The burden of untreated hepatitis C virus infection: a US patients’ perspective. Dig Dis Sci 2012;57:2995-3003
- Office National Statistics. Pension trends – Chapter 11: Pensioner income and expenditure. Crown Publishing. Office National Statistics; 2012
- Office National Statistics. The effects of taxes and benefits on household income: financial year ending 2015. Crown Publishing. Office National Statistics; 2015. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/personalandhouseholdfinances/incomeandwealth/bulletins/theeffectsoftaxesandbenefitsonhouseholdincome/financialyearending2015
- HIV Scotland & Hepatitis Scotland. Welfare reform in Scotland: the impact on people living with HIV and viral hepatitis. July 2014. Available at: www.hivscotland.com
- Department for Work and Pensions. Benefit and pension rates; 13 January 2015. Crown copyright. London: TSO. ISBN 978 0 11 7025134
- HM Treasury. The Green Book, appraisal and evaluation in central Government. London: TSO; July 2011. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/220541/green_book_complete.pdf
- Walshe K, Coleman A, McDonald R, et al. Health and social care devolution: the Greater Manchester experiment: BMJ. 2016;352:i1495
- Black D. Dame Carol Black’s review of the health of Britain’s working age population. Working for a healthier tomorrow. Available at: http://www.dwp.gov.uk/docs/hwwb-working-for-a-healthier-tomorrow.pdf
- Jit M, Hutubessy R, Png ME, et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med. 2015;13:209
- Tandon N, Reddy KR, Balart LA, et al. Direct and indirect cost burden of chronic hepatitis C. Am J Pharm Benefits. 2015;7:e90-e100
- Grishchenko M, Grieve RD, Sweeting MJ, et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009;25:171-80
- Cardoso A-C, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-7
- Siebert U, Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Soci. Int J Technol Assess Health Care 2005;21:55-65
- Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72
- Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11:1–205, iii